Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A lipodystrophy characterized by the association of lipoatrophy of the upper part of the body and lipohypertrophy of the thighs.
Biomarker and diagnostic research for acquired partial lipodystrophy has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
8 clinical trials registered, 6 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 1 PHASE4, 1 PHASE3, 3 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07091734](https://clinicaltrials.gov/study/NCT07091734) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 12:29 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about acquired partial lipodystrophy
Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024
PHASE2 |
University of Michigan |
RECRUITING |
[NCT02262806](https://clinicaltrials.gov/study/NCT02262806) | Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy | PHASE2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | ACTIVE_NOT_RECRUITING |
[NCT03900286](https://clinicaltrials.gov/study/NCT03900286) | Low Energy Diet and Familial Partial Lipodystrophy | NA | Cambridge University Hospitals NHS Foundation Trust | RECRUITING |
[NCT05470504](https://clinicaltrials.gov/study/NCT05470504) | Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance | PHASE2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | RECRUITING |
[NCT06484868](https://clinicaltrials.gov/study/NCT06484868) | Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy | PHASE4 | Amryt Pharma | RECRUITING |
20 publications have been identified in PubMed for acquired partial lipodystrophy. Research spans Case Report / Case Series (45%), Review / Meta-Analysis (30%), and Diagnostic / Biomarker (10%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 9 | 45% |
Research summaries | 6 | 30% |
Testing and diagnosis research | 2 | 10% |
Disease patterns and progression | 2 | 10% |
New treatment approaches | 1 | 5% |
Quinn K (2026). [PMID: 29083781](https://pubmed.ncbi.nlm.nih.gov/29083781/). *Unknown Journal*. [Review / Meta-Analysis]
Hirachan S (2026). [PMID: 42069552](https://pubmed.ncbi.nlm.nih.gov/42069552/). *BMC Surg*. [Case Report / Case Series]
Brandt J (2026). [PMID: 41812573](https://pubmed.ncbi.nlm.nih.gov/41812573/). *J Plast Reconstr Aesthet Surg*. [Review / Meta-Analysis]
Wang SH (2026). [PMID: 41869673](https://pubmed.ncbi.nlm.nih.gov/41869673/). *Front Oncol*. [Case Report / Case Series]
Georgescu D (2026). [PMID: 41598310](https://pubmed.ncbi.nlm.nih.gov/41598310/). *Life (Basel, Switzerland)*. [Case Report / Case Series]
Kaewkrasaesin C (2025). [PMID: 40435301](https://pubmed.ncbi.nlm.nih.gov/40435301/). *The Journal of clinical endocrinology and metabolism*. [Epidemiology / Natural History]
Ceccarini G (2025). [PMID: 41152002](https://pubmed.ncbi.nlm.nih.gov/41152002/). *European journal of endocrinology*. [Epidemiology / Natural History]
Pliszka M (2025). [PMID: 40565151](https://pubmed.ncbi.nlm.nih.gov/40565151/). *International journal of molecular sciences*. [Review / Meta-Analysis]
Ancona G (2025). [PMID: 40340619](https://pubmed.ncbi.nlm.nih.gov/40340619/). *Current medical research and opinion*. [Case Report / Case Series]
Al-Jawad M (2025). [PMID: 40154074](https://pubmed.ncbi.nlm.nih.gov/40154074/). *International journal of surgery case reports*. [Case Report / Case Series]
AI-curated news mentioning acquired partial lipodystrophy
Updated Aug 3, 2026
A multicenter study provides new insights into the clinical and metabolic characteristics of acquired partial lipodystrophy. This research enhances understanding of the disease's impact on patients and may inform future therapeutic strategies.